N/A N=401 Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
Abdominal Aortic Aneurysm · Iliac Aneurysm · Internal Iliac Aneurysm
Primary: Freedom From Aneurysm Rupture — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,366 Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts
Thoracoabdominal Aneurysm · Abdominal Aortic Aneurysm
Primary: Freedom From Aneurysm Rupture — 22 Participants
N/A N=192 Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial
Abdominal Aortic Aneurysm
Primary: Treatment Success as Defined as the Composite of Procedural Technical Success, Absence of Vascular Complications, and Absence of Major Adverse Events as Determined by…
N/A N=600 Hydrogel Endovascular Aneurysm Treatment Trial
Cerebral Aneurysm
Primary: Number of Patients With Aneurysm Recurrence Post Surgery — 11; 41 participants — p=0.002
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions
Phase 3 N=36 Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device
Intracranial Aneurysms
Primary: Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks) — 95…
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
N/A N=32 everlinQ Endovascular Access System Enhancements (EASE) Study
Chronic Kidney Diseases
Primary: Number of Participants With Protocol-Defined endoAVF Maturation — 29 Participants
N/A N=98 EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study
Abdominal Aortic Aneurysm Without Rupture
Primary: Safety: Major Adverse Events (MAE) — 1; 2; 2 Number of Events
N/A N=1,204 Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
Peripheral Arterial Occlusive Disease
Primary: Procedural Success of Endovascular PAD Treatment(s) — 83.6; 75.8; 68.5 percent of procedures
N/A N=120 CorPath® GRX Neuro Study
Intracranial Aneurysm · Subarachnoid Hemorrhage · Headache
Primary: Number of Participants With Procedural Technical Success. — 110 Participants
Phase 3 N=100 To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
Aneurysm, Dissecting · Aortic Aneurysm, Thoracic
Primary: Percentage of Participants With Technically Successful Implant — 99.0 percentage of participants
N/A N=634 Angio-Seal Interventional Radiology (IR) Registry
Diagnostic and/or Interventional Radiology Procedures
Primary: Rate of Major Vascular Complications — 0.7 Percentage of Procedures
N/A N=55 The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation
Carotid Artery Diseases · Carotid Atherosclerosis · Carotid Stenosis
Primary: Incidence of Ipsilateral New White Lesions, by Patient — 12 Participants
N/A N=1,500 Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study
Carotid Artery Disease
Primary: Composite Rate of Death, Ipsilateral CVA, Procedure-related CVA, or Myocardial Infarction (MI) at 30 Days Post-procedure. — 99 participants
N/A N=20 Prospective Randomized Endovascular Therapy in Multiple Sclerosis
Multiple Sclerosis
Primary: Percentage of Patients With Immediate and Short-term SAE — 0; 0 Participants
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease II
Peripheral Arterial Disease
Primary: Clinical Success — 20 Participants
N/A N=100 LSA Reconstruction With Laser Fenestration During the TEVAR
Type B Aortic Dissection
Primary: Freedom From All-cause Reintervention, All-cause Mortality and Major Adverse Events Within 30 Days After Procedure — 84 Participants
N/A N=194 Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System
Abdominal Aortic Aneurysms
Primary: Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure) — 88.6; 96.0 percentage of participants
N/A N=204 AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
N/A N=20 Self-Centering Guide Catheter Feasibility Study
Aortic Stenosis
Primary: Number of Self-Centering Guide Catheters Successfully Used to Deliver a Guide Wire Through the Self-Centering Guide Catheter Across the Stenotic Native Aortic Valve Into…
N/A N=38 Endovascular Denervation Improves Limb Ischemia in Patients With Peripheral Artery Disease
PAD
Primary: Change of Ankle Brachial Index (ABI) at 6-month Post-procedure. — 0.24; 0.44 ratio
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
Early Phase 1 N=453 Endovascular Recanalization and Standard Medical Management for Symptomatic Nonacute Intracranial Artery Occlusion Trial
Intracranial Artery Occlusion With Infarction
Primary: Primary Outcome — 27; 21 Participants
Phase 4 N=881 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)
Aortic Aneurysm
Primary: All-cause Mortality — 146; 146 participants — p=0.81
N/A N=222 EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants